arrow_back Back to App

Stopping Drug Monopolies: Faster Access to Affordable Generic Medicines

New rules aim to speed up the market entry of cheaper generic and biosimilar drugs. The Federal Trade Commission (FTC) gains tools to penalize companies that intentionally delay this process by filing baseless petitions. This could lead to lower drug prices and more choices for patients.
Key points
The FTC can penalize companies filing baseless petitions to delay generic drug approval.
Financial penalties can be substantial, including revenue from drug sales or $50,000 per day of delay.
The goal is to increase competition in the pharmaceutical market and facilitate access to more affordable medicines.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_1425
Sponsor: Sen. Klobuchar, Amy [D-MN]
Process start date: 2021-04-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Stop STALLING Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_1425.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-04-28.

What are the main provisions?

Key points include:

  • The FTC can penalize companies filing baseless petitions to delay generic drug approval.
  • Financial penalties can be substantial, including revenue from drug sales or $50,000 per day of delay.
  • The goal is to increase competition in the pharmaceutical market and facilitate access to more affordable medicines.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Klobuchar, Amy [D-MN].

What is the latest detailed status?

The latest detailed status is: Placed on Senate Legislative Calendar under General Orders. Calendar No. 179.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health Courts and Law Economy